a) Identify populations at risk of allergies and respiratory
b) Evaluate the professional practices regarding the management of chronic diseases including allergic and primary care
The reported prevalence of allergy and drug hypersensitivity represents a public health problem. Pharmacovigilance algorithms currently available do not identify individuals who may be allergic / hypersensitive to drugs. However, the accurate diagnosis of allergy has an impact on costs but also on the optimal use of antibiotics. The center will develop the project Galenda on drug allergy, combining a network of experts, international recommendations, all standard procedures for drug allergy, a database and network of excellence EU for information dissemination and education of allergy. More specifically:
• Optimize the basis DAHD (Drug Allergy and Hypersensitivity Database). Coding based on standardized questionnaire takes DAHD ENDA. To allow a better exploitation of data, this questionnaire will integrate the dictionary MEDRA (Medical Dictionary for Regulatory Activities), dictionary that will be available on DAHD.
• The network will allow the detection of new phenotypes and endotypes (such as identification and detection). A comprehensive database will enhance epidemiological knowledge and identification of risk factors.
• Develop algorithms specific to allergy pharmacovigilance / drug hypersensitivity. Spontaneous reports are the main sources of information databases for pharmacovigilance. However, it is commonly assumed that these bases underestimate the prevalence of allergic reactions and they often focus on the most severe reactions, without being the most common. Also in the case of allergic reaction / hypersensitivity drug, these databases collect information without being able to demonstrate a true allergic reaction and hypersensitivity. It is therefore interesting to link reports pharmacovigilances with diagnostic features provided by the centers investigating and exploring the suspected allergy / drug hypersensitivity. The platform Galenda interacts with networks of pharmacovigilance and diagnostic centers to promote substantiated. The objective is to accelerate the generation of reliable pharmacoepidemiological to promote proactive pharmacovigilance and risk management of medicines throughout their lifecycle. EMA is currently developing a European network "European Network for Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP) (www.emea.europa.eu)" and binds Galenda platform links the network through the center of Amsterdam ( Netherlands) and Munich (Germany) (I Tereehorst, Brockow K). The storage of samples referred to diagnostic or research will be done GA2LEN BioBank Center, Karolinska Institute (Stockholm) using the methodology developed by GA2LEN F Kauffmann and Cambon-Thomsen A. They participated in the definition of the legal aspects of the exchange of biological and genetic samples (53) and have developed an interface (Quality management of Biobanks: GA ² LEN handbook for Researchers, http://ga2len.net) in collaboration with the project EU BBMRI (Biobanking and Biomolecular Resources Research Infrastructure).